BRUSSELS (Reuters) - The head of the European Union?s medicines agency Guido Rasi said on Monday an initial authorisation for U.S. pharmaceutical company Gilead?s remdesivir as a COVID-19 treatment could be granted in coming days. The European Medicines Agency (EMA) has already recommended the compassionate use of remdesivir, which allows a drug to be administered to patients even before it has been fully authorised. ?It might be that a conditional market authorisation can be issued in the coming days,? Rasi told a hearing in the EU Parliament in Brussels. Apart from remdesivir, Rasi said other possible treatments against COVID-19 that may be available fast are those based on monoclonal antibodies, which can ?neutralize? the new coronavirus (SARS-CoV-2) that causes the illness COVID-19